A government evaluation to include a specific CBD formulation in Brazil’s Public Health System (SUS) has been postponed. The National Committee for Health Technology Incorporation (Conitec), a government agency, had been scheduled to take up the issue this week. Instead, the evaluation will now occur in early 2021. However, Tarso Araujo, chief business development officer for São Paulo, Brazil-based Entourage Phytolab told Marijuana Business Daily he’d be “surprised” if a product without finished clinical trials proving safety and efficacy is included in SUS coverage. “Moreover, its high price doesn’t help pass the cost-benefit consideration that the Conitec must do,” Araujo said. Some experts in Brazil also think the government move to include CBD in the SUS seeks to undermine a bill to allow in-country cannabis cultivation.
Marijuana Business Daily, 12/10/2020 09:01:00